$2.63 Billion is the total value of Tekla Capital Management LLC's 222 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| INO | New | Inovio Pharmaceuticals, Inc. | $5,445,000 | – | 202,038 | +100.0% | 0.21% | – |
| MOH | New | Molina Healthcare, Inc. | $4,901,000 | – | 27,536 | +100.0% | 0.19% | – |
| AMED | New | Amedisys, Inc. | $3,851,000 | – | 19,395 | +100.0% | 0.15% | – |
| PRNB | New | Principia Biopharma Inc. | $3,611,000 | – | 60,390 | +100.0% | 0.14% | – |
| KRTX | New | Karuna Therapeutics, Inc. | $3,330,000 | – | 29,873 | +100.0% | 0.13% | – |
| CRBP | New | Corbus Pharmaceuticals Holdings, Inc. | $3,177,000 | – | 378,706 | +100.0% | 0.12% | – |
| DXCM | New | DexCom, Inc. | $2,940,000 | – | 7,251 | +100.0% | 0.11% | – |
| ADUS | New | Addus HomeCare Corp. | $1,478,000 | – | 15,969 | +100.0% | 0.06% | – |
| ASRT | New | Assertio Holdings, Inc. | $1,407,000 | – | 1,642,302 | +100.0% | 0.05% | – |
| TCDA | New | Tricida, Inc. | $1,384,000 | – | 50,370 | +100.0% | 0.05% | – |
| New | Innate Pharma SAsponsored ads | $858,000 | – | 137,734 | +100.0% | 0.03% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Gilead Sciences, Inc. | 41 | Q2 2023 | 12.4% |
| Amgen, Inc. | 41 | Q2 2023 | 5.8% |
| Biogen Inc. | 41 | Q2 2023 | 6.5% |
| Vertex Pharmaceuticals Incorporated | 41 | Q2 2023 | 5.3% |
| Regeneron Pharmaceuticals, Inc. | 41 | Q2 2023 | 9.1% |
| Illumina, Inc. | 41 | Q2 2023 | 3.4% |
| BioMarin Pharmaceutical Inc. | 41 | Q2 2023 | 2.9% |
| Teva Pharmaceutical Industries Ltd. | 41 | Q2 2023 | 3.2% |
| Neurocrine Biosciences, Inc. | 41 | Q2 2023 | 1.4% |
| McKesson Corporation | 41 | Q2 2023 | 2.2% |
View Tekla Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rallybio Corp | January 23, 2023 | 1,727,067 | 4.6% |
| Zyla Life SciencesSold out | January 29, 2021 | 0 | 0.0% |
| ARCA biopharma, Inc. | January 24, 2020 | 36,068 | 2.3% |
| Verona Pharma plc | February 12, 2019 | 5,296,845 | 4.9% |
| Alliqua BioMedical, Inc. | February 12, 2018 | 165,000 | 3.3% |
| PIERIS PHARMACEUTICALS, INC. | February 12, 2018 | 1,962,380 | 4.4% |
| Intellipharmaceutics International Inc. | February 13, 2015 | 2,184,000 | 9.0% |
| HERON THERAPEUTICS, INC. /DE/ | February 14, 2014 | 20,598,613 | 4.2% |
| MEDWAVE INC | February 14, 2012 | 1,277,372 | 9.8% |
| MZT Holdings, Inc. | February 14, 2012 | 2,553,420 | 4.0% |
View Tekla Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2023-08-10 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-10 |
| SC 13G/A | 2023-01-23 |
| 13F-HR | 2022-11-01 |
| 13F-HR | 2022-07-29 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-14 |
| SC 13G | 2022-01-21 |
| 13F-HR | 2021-11-12 |
View Tekla Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.